Terapia combinada con infliximab y upadacitinib en espondiloartritis periférica refractaria asociada a enfermedad de Crohn. // Medicina Clínica. – URL: https://www.sciencedirect.com/science/article/pii/S0025775326002472?dgcid=rss_sd_all
Terapia combinada con infliximab y upadacitinib en espondiloartritis periférica refractaria asociada a enfermedad de Crohn. Medicina Clínica. https://www.sciencedirect.com/science/article/pii/S0025775326002472?dgcid=rss_sd_all
“Terapia combinada con infliximab y upadacitinib en espondiloartritis periférica refractaria asociada a enfermedad de Crohn.” Medicina Clínica.
@article{article94730,
title = {Terapia combinada con infliximab y upadacitinib en espondiloartritis periférica refractaria asociada a enfermedad de Crohn},
journal = {Medicina Clínica},
url = {https://www.sciencedirect.com/science/article/pii/S0025775326002472?dgcid=rss_sd_all}
}
ABSTRACT As leadership education continues to evolve, increasing attention has been given to fostering learners’ leadership identity, capacity, and efficacy. Drawing on collaborative conversations with 12 leadership educators...